Inspection Record

Aurobindo Pharma Limited, Unit VII — FDA 483 Findings

US FDAInspected 2026-02-10Published 2026-02-20 8 findingsEquipment and facilityLaboratory and QC controlsComputer system validationComplaint and recall handlingQuality unit oversightDeviation, CAPA, and investigationDocumentation and records

Inspectors Guerlain Ulysse · Nibin VargheseThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Equipment and facility

Equipment and utensils are no1 cleaned at appropriate intervals to prevent that would alter the safety, identity, strength, quality or purity ofthe drug product.

2Laboratory and QC controls

Established laboratory control mechanisms are not followed.

3Computer system validation

Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.

4Laboratory and QC controls

Laboratory records are deficient in that they do not include a complete record ofall data obtained during testing.

5Complaint and recall handling

Complaints records arc deficient in that they do not include the findings ofthe investigation and follow­ up.

6Quality unit oversight

The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.

7Deviation, CAPA, and investigation

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

8Documentation and records

Master production and control records lack complete manufacturing and control instructions, sampling and testing procedures.

About this record

Extracted automatically from the document US FDA published on 2026-02-20. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Aurobindo Pharma Limited, Unit VII company profile — full history US FDA documents, 2026 Go to Findings search